Melatonin ameliorates skeletal dysplasia of Col2a1-CreERT2;Slc26a2fl/fl mice. (IMAGE)
Caption
(A) Overview of the drug delivery plan. Tamoxifen was administered to mice at a dosage of 1 mg per 10 g body weight per day, for consecutive 5 days from P10 to P14 and then every three days from P10 to P49. Melatonin was given from P10 to P49. (B) Gross appearance of mice at 7 weeks of age following the administration of tamoxifen and melatonin treatment. (C, D) Statistical analyses of body weight and body length. (E) Micro-CT reconstruction of the skeleton at P49. (F–H) Tibial radiography and statistical analysis. (I, J) Micro-CT assessment of bone microstructure and statistical analysis. Statistical significance was assessed through One-way ANOVA followed by Tukey's multiple comparisons test. The results are presented as mean ± standard deviation, with ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, and ∗∗∗∗P < 0.0001 indicating statistical significance, while “ns” denotes no statistical significance. SLC26A2, Solute carrier family 26 member 2; CTR, cre-negative control.
Credit
Genes & Diseases
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted. No derivatives or adaptations of the work are permitted.
License
CC BY-NC-ND